AASLD PRACTICE GUIDELINES
Diagnosis and Treatment of Autoimmune Hepatitis
Albert J. Czaja1 and Deborah K. Freese1,2
Preamble
These guidelines provide a data-supported approach to
the diagnosis and management of patients with autoim-
mune hepatitis. They are based on the following: (1) a
formal review and analysis of the published world litera-
ture on autoimmune hepatitis (914 articles) (Medline
Search from 1966-2002; the search term was autoim-
mune hepatitis); (2) recommendations developed and
published by the International Autoimmune Hepatitis
Group; (3) concepts developed at the AASLD Single
Topic Conference on autoimmune hepatitis in Septem-
ber 1999; and (4) 40 years of combined experience by
both authors in the clinical and laboratory investigation
and care for patients with this disease. The guidelines,
intended for use by physicians, are meant to be flexible, in
contrast to “standards of care,” which are inflexible poli-
cies to be followed in almost every case. They have been
developed in a manner consistent with the American As-
sociation for the Study of Liver Diseases’ Policy Statement
on Development and Use of Practice Guidelines.
Specific recommendations are based on relevant pub-
lished information. In an attempt to standardize recom-
mendations, the Practice Guidelines Committee of the
American Association for the Study of Liver Diseases
modified the categories of the Infectious Diseases Society
of America’s Quality Standards. These categories are re-
ported with each recommendation, using the Roman nu-
merals I through IV to determine the quality of evidence
upon which the recommendations are based. The catego-
ries are as follows: I, evidence from multiple well-designed
randomized controlled trials, each involving a number of
participants to be of sufficient statistical power; II, evi-
dence from at least one large, well-designed clinical trial
with or without randomization, from cohort or case-con-
trol analytic studies, or from well-designed meta-analysis;
III, evidence based on clinical experience, descriptive
studies, or reports of expert committees; and IV, not
rated.
Background
Autoimmune hepatitis (AIH) is an unresolving inflam-
mation of the liver of unknown cause.1 It is characterized
by the presence of interface hepatitis and portal plasma
cell infiltration on histologic examination, hypergamma-
globulinemia, and autoantibodies.1,2 Autoimmune hepa-
titis reflects a complex interaction between triggering
factors, autoantigens, genetic predispositions, and immu-
noregulatory networks.3,4 The mean annual incidence of
AIH among white Northern Europeans is 1.9 per
100,000, and its point prevalence is 16.9 per 100,000.5 It
accounts for 2.6% of the transplantations in Europe6 and
5.9% in the United States.7 Women are affected more
than men (gender ratio, 3.6:1),8 and all ages9,10 and ethnic
groups10-14 are susceptible.
A prospective study has indicated that as many as 40%
of patients with untreated severe disease die within 6
months of diagnosis.15 Cirrhosis develops in at least 40%
of survivors16; 54% develop esophageal varices within 2
years after cirrhosis17; and 20% of individuals with esoph-
ageal varices die from hemorrhage.17 Sustained serum
aminotransferase levels of more than 10-fold normal or
more than 5-fold normal in conjunction with serum
�-globulin concentrations at least 2-fold normal identify
patients with early mortality.15 Bridging necrosis or mul-
tiacinar necrosis on histologic examination progresses to
cirrhosis in 82% of patients within 5 years, and mortality
is 45%.18 Patients with less severe laboratory and histo-
logic findings fare better, but cirrhosis still develops in
49% within 15 years and death from hepatic failure oc-
curs in 10%.19 An acute onset of illness is common
(40%),20-23 and a fulminant presentation, characterized
by hepatic encephalopathy within 8 weeks of disease on-
set, is possible.24
Three randomized, controlled treatment trials pub-
lished between 1971 and 1974 have established that pred-
nisone alone or in combination with azathioprine
improves symptoms, laboratory tests, histologic findings,
and immediate survival.15,17,25 Liver transplantation has
been associated with 5-year patient and graft survivals that
Abbreviations: AIH, autoimmune hepatitis; ANA, antinuclear antibodies;
SMA, smooth muscle antibodies; anti-LKM1; antibodies to liver/kidney microsome
type 1; anti-ASGPR, antibodies to asialoglycoprotein receptor; anti-LC1, antibodies
to liver-specific cytosol antigen type 1; anti-SLA/LP, antibodies to soluble liver
antigen/liver pancreas; pANCA, perinuclear anti-neutrophil cytoplasmic antibod-
ies; APECED, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.
From the 1Divisions of Gastroenterology and Hepatology and 2Pediatric Gastro-
enterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, MN.
Address reprint requests to: Albert J. Czaja, M.D., Mayo Clinic, 200 First Street
S.W., Rochester, MN 55905. E-mail: czaja.albert@mayo.edu;fax: 507-284-0538.
Copyright © 2002 by the American Association for the Study of Liver Diseases.
0270-9139/02/3602-0028$35.00/0
doi:10.1053/jhep.2002.34944
479
exceed 80%,26,27 and recurrent disease after transplanta-
tion has been usually mild and manageable.6,28-35 In chil-
dren, recurrence after transplantation occurs more
frequently and may be more difficult to treat.35
Diagnostic Criteria
Diagnosis requires the presence of characteristic fea-
tures and the exclusion of other conditions that resemble
AIH.36,37 Interface hepatitis (Fig. 1) is the histologic hall-
mark of the syndrome,2 and portal plasma cell infiltration
(Fig. 2) typifies the disorder.2,36-38 Neither histologic
finding is disease specific, and the absence of portal
plasma cells does not preclude the diagnosis. All patients
suspected of AIH must be evaluated for hereditary (Wil-
son disease, �1 antitrypsin deficiency, and genetic hemo-
chromatosis), infectious (hepatitis A, B, and C infection),
and drug-induced (minocycline, nitrofurantoin, isonia-
zid, propylthiouracil, and �-methyldopa) liver injury,
some of which may have autoimmune features. The con-
ditions most likely to be confused with AIH are Wilson
disease, drug-induced hepatitis, and chronic viral hepati-
tis, especially chronic hepatitis C.39-41
Liver biopsy examination is essential to establish the
diagnosis and evaluate disease severity to determine the
need for treatment. Serum aminotransferase and �-glob-
ulin levels do not predict the histologic pattern of injury
or the presence or absence of cirrhosis.42 Histologic
changes, such as ductopenia or destructive cholangitis,
may indicate a variant syndrome of AIH and primary
sclerosing cholangitis, AIH and primary biliary cirrhosis,
or autoimmune cholangitis,43-46 and the findings of ste-
atosis or iron overload may suggest alternative diagnoses,
such as nonalcoholic fatty liver disease, Wilson disease,
chronic hepatitis C, drug toxicity, or genetic hemochro-
matosis.47 Autoantibodies must be present, and the con-
ventional serologic markers of AIH are antinuclear
antibodies (ANA), smooth muscle antibodies (SMA), and
antibodies to liver/kidney microsome type 1 (anti-
LKM1).48,49
Diagnostic criteria have been codified and updated by
an international panel (Table 1).36,37 Differences between
a definite and probable diagnosis of AIH relate mainly to
the degree of serum �-globulin or immunoglobulin G
elevation, levels of ANA, SMA, or anti-LKM1, and expo-
sures to alcohol, medications, or infections that could
cause liver injury. There is no time requirement to estab-
lish chronicity, and cholestatic clinical, laboratory, and
histologic changes preclude the diagnosis. The presence of
antibodies to asialoglycoprotein receptor (anti-ASGPR),
liver-specific cytosol antigen type 1 (anti-LC1), soluble
liver antigen/liver pancreas (anti-SLA/LP), actin (anti-ac-
tin), and/or perinuclear anti-neutrophil cytoplasmic anti-
bodies (pANCA) support a probable diagnosis if the other
conventional markers are absent.
A scoring system has been proposed to assess the
strength of the diagnosis (Table 2).36,37 By weighing each
component of the syndrome, discrepant features can be
accommodated (normal serum �-globulin level50) and bi-
ases associated with isolated inconsistencies (destructive
cholangitis45) can be avoided. Autoimmune hepatitis typ-
ically enters remission during corticosteroid therapy and
frequently relapses after drug withdrawal. These charac-
teristic post-treatment responses have also been incorpo-
rated into the scoring system. The score based on
pretreatment features can be upgraded or downgraded by
the response to treatment, and inconsistent findings that
Fig. 2. Plasma cell infiltrate. Plasma cells are identified by their
eccentric, clock-face nucleus and pale perinuclear cytoplasmic crescent.
They are characteristic of autoimmune hepatitis, but neither pathogno-
monic of the disease or required for its diagnosis. Staining by hematox-
ylin-eosin; original magnification �400.
Fig. 1. Interface hepatitis. The portal tract is expanded by a mono-
nuclear infiltrate; the limiting plate is disrupted; and the inflammatory
process extends into the acinus. Staining by hematoxylin-eosin; original
magnification �200.
480 CZAJA AND FREESE HEPATOLOGY, August 2002
Table 1. Diagnostic Criteria for Autoimmune Hepatitis
Requisites
Diagnostic Criteria
Definite Probable
No genetic liver
disease
Normal �1 antitrypsin phenotype Partial �1 antitrypsin deficiency
Normal serum ceruloplasmin, iron, and ferritin levels Nonspecific serum copper, ceruloplasmin, iron, and/or ferritin
abnormalities
No active viral
infection
No markers of current infection with hepatitis A, B, and C viruses No markers of current infection with hepatitis A, B, and C viruses
No toxic or alcohol
injury
Daily alcohol � 25 g/d and no recent use of hepatotoxic drugs Daily alcohol � 50 g/d and no recent use of hepatotoxic drugs
Laboratory features Predominant serum aminotransferase abnormality Predominant serum aminotransferase abnormality
Globulin, �-globulin or immunoglobulin G level � 1.5 times normal Hypergammaglobulinemia of any degree
Autoantibodies ANA, SMA, or anti-LKM1 � 1:80 in adults and �1:20 in children;
no AMA
ANA, SMA, or anti-LKM1 � 1:40 in adults or other autoantibodies*
Histologic findings Interface hepatitis Interface hepatitis
No biliary lesions, granulomas, or prominent changes suggestive of
another disease
No biliary lesions, granulomas, or prominent changes suggestive of
another disease
Abbreviation: AMA, antimitochondrial antibodies.
*Includes perinuclear anti-neutrophil cytoplasmic antibodies and the not generally available antibodies to soluble liver antigen/liver pancreas, actin, liver cytosol type
1, and asialoglycoprotein receptor.
Based on recommendations of the International Autoimmune Hepatitis Group (J Hepatol 1999;31:929-938).
Table 2. Diagnostic Scoring System for Atypical Autoimmune Hepatitis in Adults
Category Factor Score Category Factor Score
Gender Female �2 Concurrent immune disease Any nonhepatic disease of an immune nature �2
Alk Phos:AST (or ALT) ratio �3
�1.5
�2
�2
Other autoantibodies* Anti-SLA/LP, actin, LC1, pANCA �2
�-globulin or IgG
(times above upper limit of normal)
�2.0
1.5-2.0
1.0-1.5
�1.0
�3
�2
�1
0
Histologic features Interface hepatitis
Plasma cells
Rosettes
None of above
Biliary changes†
Atypical features‡
�3
�1
�1
�5
�3
�3
ANA, SMA, or anti-LKM1 titers �1:80
1:80
1:40
�1:40
�3
�2
�1
0
HLA DR3 or DR4 �1
AMA Positive �4 Treatment response Remission alone
Remission with relapse
�2
�3
Viral markers of active infection Positive
Negative
�3
�3
Hepatotoxic drugs Yes
No
�4
�1
Pretreatment score
Definite diagnosis
Probable diagnosis
�15
10-15
Alcohol �25 g/d
�60 g/d
�2
�2
Posttreatment score
Definite diagnosis
Probable diagnosis
�17
12-17
Abbreviations: Alk phos, serum alkaline phosphatase level; AST, serum aspartate aminotransferase level; ALT, serum alanine aminotransferase level; IgG, serum
immunoglobulin G level; AMA, antimitochondrial antibodies; HLA, human leukocyte antigen.
*Unconventional or generally unavailable antibodies associated with liver disease include perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) and antibodies
to actin, soluble liver antigen/liver pancreas (anti-SLA/LP), asialoglycoprotein receptor (ASGPR), and liver cytosol type 1 (LC1).
†Includes destructive cholangitis, nondestructive cholangitis, or ductopenia.
‡Includes steatosis, iron overload consistent with genetic hemochromatosis, alcohol-induced hepatitis, viral features (ground-glass hepatocytes), or inclusions
(cytomegalovirus, herpes simplex).
Based on recommendations of the International Autoimmune Hepatitis Group (J Hepatol 1999;31:929-938).
HEPATOLOGY, Vol. 36, No. 2, 2002 CZAJA AND FREESE 481
do not affect treatment response may not alter the diag-
nosis. The definite diagnosis prior to corticosteroid treat-
ment requires a score greater than 15, whereas the definite
diagnosis after corticosteroid treatment requires a score
greater than 17 (Table 2).
The original scoring system has been validated against
AIH and other chronic liver diseases. The sensitivity of
the scoring system for AIH ranges from 97% to
100%,50-52 and its specificity for excluding AIH in pa-
tients with chronic hepatitis C ranges from 66% to
92%.52-54 In most instances, the scoring system is unnec-
essary for the diagnosis of AIH since the clinical, labora-
tory, and histologic components of the syndrome are
usually well defined.50 The major value of the scoring
system may be in the objective assessment of variant
or atypical syndromes that resemble the classical di-
sease.43-46,55 Its major weakness has been in excluding
cholestatic syndromes with autoimmune features. Among
these disorders, the ability of the scoring system to exclude
AIH has ranged from 45% to 65%.50,55 This weakness has
justified revision of the scoring system to further down-
grade cholestatic findings.37 Preliminary assessments of
the revised system by retrospective analysis of prospec-
tively acquired patient data have indicated a better perfor-
mance in excluding biliary diseases.56
The diagnostic criteria for children are different from
those of adults.36,37 Autoantibody titers tend to be lower
in children, and the presence of autoantibodies in any
titer, in combination with other requisite elements, is suf-
ficient to support a definite diagnosis (Table 1). Autoan-
tibodies are neither pathogenic nor disease specific,49 and
their expression can vary during the course of AIH.57 A
single low autoantibody titer should never exclude the
diagnosis of AIH in an adult or child, nor should high
titers establish the diagnosis in the absence of other sup-
portive findings. Seronegative individuals may be classi-
fied at presentation as having cryptogenic chronic
hepatitis until conventional markers appear later in the
course57-59 or until autoantibodies that are not generally
available are tested.60,61 Autoantibody titers reflect the
strength of the immune response, and they are useful only
in diagnostic schemes to complement other features that
support the diagnosis of AIH. Autoantibodies do not
cause the disease nor do their levels reflect response to
treatment. Accordingly, they do not need to be moni-
tored.36,37,41,46
A unique form of sclerosing cholangitis in children
(sometimes termed “autoimmune sclerosing cholangitis”)
has been described in a single center.62,63 This disease may
mimic classic AIH, and cholangiography is often needed
to distinguish the disorders. The small number of re-
ported cases, the lack of general agreement regarding the
nature of the process, and the absence of a treatment
consequence do not compel the routine performance of
cholangiography in the initial evaluation.
Conventional Repertoire of Autoantibodies
ANA, SMA, and anti-LKM1 should be determined in
all patients with clinical, laboratory, and/or histologic fea-
tures that suggest the diagnosis of AIH, and they consti-
tute the conventional repertoire of autoantibodies for this
condition.36,37
ANA are the traditional markers of AIH, and they are
present alone (13%) or with SMA (54%) in 67% of pa-
tients with the disease.57 Nuclear reactivity can be assessed
by indirect immunofluorescence on Hep-2 cell lines64 or
by an enzyme immunoassay using microtiter plates with
adsorbed recombinant or highly purified antigens.65 The
nuclear targets of ANA in AIH are uncertain, and many
ANA in AIH are nonreactive to the major recombinant
nuclear antigens.64 Some medical centers, therefore, pre-
fer to assess ANA by indirect immunofluorescence until
the performance parameters of enzyme immunoassay in
AIH are fully defined.
ANA in AIH react against diverse recombinant nuclear
antigens, including centromere, ribonucleoproteins, and
ribonucleoprotein complexes.64 None of these reactivities
has been associated with a specific pattern of indirect im-
munofluorescence or prognostic importance.64 Further-
more, the patterns of indirect immunofluorescence
(homogenous versus speckled) have had no clinical signif-
icance.66 ANA can be found in primary biliary cirrho-
sis,67,68 primary sclerosing cholangitis,69,70 chronic viral
hepatitis,71,72 drug-related hepatitis,73,74 nonalcoholic ste-
atohepatitis,47,75 and alcohol-induced liver disease,76,77
and their expression can be variable in the same patient.57
SMA are directed against actin and nonactin compo-
nents, including tubulin, vimentin, desmin, and skeletin,
and they are also standard markers of AIH.48,49,78-80 SMA
are present in 87% of patients with AIH, either as the sole
marker of the disease (33%) or in conjunction with ANA
(54%).57 Three types have been described using cultured
fibroblasts treated with vinblastine. These are antibodies
to actin, tubulin, and intermediate filaments.78-80 SMA
are present in a variety of liver and nonliver diseases, and
their utility as diagnostic markers depends on the clinical
syndrome.69-72,80 Like ANA, SMA have a variable expres-
sion in individual patients.57 Typically, SMA are dem-
onstrated in the clinical laboratory by indirect
immunofluorescence on murine stomach and kid-
ney.49,79-81
Anti-LKM1 typically occur in the absence of SMA and
ANA.82,83 Seropositivity requires reactivity against the
proximal tubules of the murine kidney and the hepato-
482 CZAJA AND FREESE HEPATOLOGY, August 2002
cytes of the murine liver by indirect immunofluores-
cence.49,83 Antibodies-LKM1 react with high specificity
to a short linear sequence of the recombinant antigen,
cytochrome mono-oxygenase CYP2D6 (P450 IID6), and
they also inhibit CYP2D6 activity in vitro.84,85 These
findings together with evidence that liver-infiltrating lym-
phocytes have specific reactivity to CYP2D6 have impli-
cated this cytochrome as an autoantigen in AIH.86
Homologies exist between CYP2D6 and the genome of
the hepatitis C virus,84 and occasionally anti-LKM1 can
be found in this infection.87-90 The absence of anti-LKM1
among patients with chronic hepatitis C in the United
States91 may relate to environmental factors, host genetic
predispositions, or regional differences in the viral geno-
type associated with anti-LKM1.92,93 The anti-LKM1
found in chronic hepatitis C in Europe react to different
epitopes on the recombinant CYP2D6 molecule than an-
ti-LKM1 associated with AIH, and these diverse reactiv-
ities distinguish the antibodies.88,94
Antibodies to LKM1 are rare in the United States,
occurring in only 4% of adults with AIH.83 They have
been described mainly in pediatric patients in Europe, but
20% of patients with anti-LKM1 in France and Germany
are adults.82 The reasons for these regional differences in
the occurrence of anti-LKM1 in AIH are unknown, but
they may reflect variable host expression of CYP2D6, ge-
netic differences in the immune response to the ta
本文档为【自身免疫性肝炎的诊断和治疗标准(AASLD)】,请使用软件OFFICE或WPS软件打开。作品中的文字与图均可以修改和编辑,
图片更改请在作品中右键图片并更换,文字修改请直接点击文字进行修改,也可以新增和删除文档中的内容。
该文档来自用户分享,如有侵权行为请发邮件ishare@vip.sina.com联系网站客服,我们会及时删除。
[版权声明] 本站所有资料为用户分享产生,若发现您的权利被侵害,请联系客服邮件isharekefu@iask.cn,我们尽快处理。
本作品所展示的图片、画像、字体、音乐的版权可能需版权方额外授权,请谨慎使用。
网站提供的党政主题相关内容(国旗、国徽、党徽..)目的在于配合国家政策宣传,仅限个人学习分享使用,禁止用于任何广告和商用目的。